ADGRL2 and Lassa fever: We have shown that Bma-LEC-1 and Bma-LEC-2 have immunomodulatory functions on host cells which provides a rationale for the potential targeting of Bma-LEC-1 and Bma-LEC-2 as a novel therapeutic to impair LF.